Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Predicting first-line VEGFR-TKI resistance and survival in metastatic clear cell renal cell carcinoma using a clinical-radiomic nomogram ; volume:24 ; number:1 ; day:11 ; month:11 ; year:2024 ; pages:1-12 ; date:12.2024
Cancer imaging ; 24, Heft 1 (11.11.2024), 1-12, 12.2024
- Urheber
-
Wang, Yichen
Zhang, Xinxin
Wang, Sicong
Shi, Hongzhe
Zhao, Xinming
Chen, Yan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40644-024-00792-7
- URN
-
urn:nbn:de:101:1-2501282140206.643392661122
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Yichen
- Zhang, Xinxin
- Wang, Sicong
- Shi, Hongzhe
- Zhao, Xinming
- Chen, Yan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
TKi | TKi
Is imatinib still the best choice as first-line oral TKI
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
TKI
TKI
TKi
TKi
"TKi"
TKi
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
TKi | TKi
Is imatinib still the best choice as first-line oral TKI
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
TKI
TKI
TKi
TKi
"TKi"
TKi
Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
Estimated cost of VEGFR TKI associated adverse events in metastatic renal cell carcinoma patients
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
TKi | TKi
Is imatinib still the best choice as first-line oral TKI
First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
TKI
TKI
TKi
TKi
"TKi"